BLU.TO - BELLUS Health Inc.

Toronto - Toronto Real Time Price. Currency in CAD

BELLUS Health Inc.

275 Armand-Frappier Boulevard
Laval, QC H7V 4A7
450 680 4500

Full Time Employees74

Key Executives

NameTitlePayExercisedYear Born
Mr. Roberto Francesco BelliniPres, CEO & Director790.35kN/A1980
Mr. Ramzi BenamarChief Financial Officer650.48kN/A1973
Dr. Andreas Orfanos FFPM, M.B.B.Ch, MBAChief Operating Officer417.58kN/A1959
Dr. Denis Garceau Ph.D.Chief Scientific Officer496.56kN/A1957
Dr. Catherine M. Bonuccelli M.D.Chief Medical Officer741.66kN/A1958
Mr. Daniel MatthewsDirector of Investor Relations & CommunicationsN/AN/AN/A
Mr. Tony MatzouranisChief Bus. OfficerN/AN/A1973
Mr. Sebastien RoyCorp. Sec.N/AN/A1976
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.


BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. BELLUS Health Inc. was incorporated in 1993 and is based in Laval, Canada.

Corporate Governance

BELLUS Health Inc.’s ISS Governance QualityScore as of June 1, 2023 is 10. The pillar scores are Audit: 4; Board: 9; Shareholder Rights: 6; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.